Journal of the Endocrine Society最新文献

{"title":"MRI-based radiomics prediction of somatostatin receptor ligand response in acromegaly: an automated pipeline study.","authors":"Sabina Ruiz, Roger Mateu-Estivill, Ariadna Izquierdo-Gómez, Miriam López-Máñez, Jesús A Alzate, Gemma Monté-Rubio, Maria de la Iglesia-Vayá, Marta Araujo-Castro, Betina Biagetti, Silvana Sarria, Federico Vázquez, Fabiola Romero, Elena Valassi, Victor Navas, Mónica Marazuela, Paloma Puyalto, Manel Puig-Domingo","doi":"10.1210/jendso/bvag198","DOIUrl":"10.1210/jendso/bvag198","url":null,"abstract":"<p><strong>Context: </strong>Radiomics may capture tumor characteristics predicting therapeutic response.</p><p><strong>Objective: </strong>To develop an MRI-based radiomics pipeline for predicting response to SRLs in acromegaly.</p><p><strong>Methods: </strong>MRI data from 267 subjects across 3 datasets were used to develop an automated tumor detection and segmentation pipeline (Spanish multicenter acromegaly IGTP cohort, <i>n</i> = 81; 2 public datasets, <i>n</i> = 186). The 3-stage pipeline comprised: (1) automated tumor detection (YOLOv8), (2) 3D segmentation (SegResNet), and (3) radiomic feature extraction (PyRadiomics) with supervised classification. Treatment-response radiomics included contrast-enhanced T1-weighted (Ce-T1W1) MRI from 49 patients treated with SRL. SRL response was defined as ≥50% IGF-1 reduction or normalization. Eleven machine-learning classifiers were evaluated using stratified repeated <i>k</i>-fold cross-validation.</p><p><strong>Results: </strong>Automated segmentation achieved a Dice coefficient of 0.795 using combined Ce-T1WI and T2-weighted images (T2WI), decreasing to 0.765 in the acromegaly-specific cohort. The best-performing model was a 3-feature logistic regression classifier, with an out-of-fold AUC of 0.798 (95% CI: 0.671-0.918), balanced accuracy of 0.793, <i>F</i>1-score of 0.815, and correct classification of 39/49 patients (79.6%). Performance improved as the radiomic feature set was reduced from 5 to 2. The most consistent feature was log-sigma-3-0-mm-3D_glcm_ClusterShade, which appeared in 98% of cross-validation folds and contributed most to the model-derived discriminative signal.</p><p><strong>Conclusion: </strong>In this multicenter radiomics study of SRL response prediction in acromegaly, an automated pipeline achieved good discriminative performance (AUC = 0.798). These findings highlight both the promise and the current challenges of radiomics-based treatment prediction.</p>","PeriodicalId":17334,"journal":{"name":"Journal of the Endocrine Society","volume":"10 10","pages":"bvag198"},"PeriodicalIF":4.4,"publicationDate":"2026-08-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13579061/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148990508","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"An observational study of menstrual function and related hormones before and after treatment of Cushing syndrome.","authors":"Brielle M Brown, Raven McGlotten, Lynnette K Nieman, Henrik Elenius","doi":"10.1210/jendso/bvag192","DOIUrl":"10.1210/jendso/bvag192","url":null,"abstract":"<p><strong>Context: </strong>Although menstrual dysfunction occurs in Cushing syndrome (CS), drivers of its prevalence and prognosis are poorly documented.</p><p><strong>Objective: </strong>Assess the prevalence of menstrual dysfunction, time to resolution after restoration of eucortisolism, and predictive factors for development and resolution.</p><p><strong>Design: </strong>Retrospective evaluation.</p><p><strong>Setting: </strong>Tertiary referral center.</p><p><strong>Patients: </strong>93 women treated for CS from 1987 to 2024.</p><p><strong>Interventions: </strong>Surgery, medical therapy, and/or irradiation to restore eucortisolism.</p><p><strong>Main outcome measures: </strong>Prevalence of affected menses; rate and time to return to baseline pattern after remission. Patient, hormonal, tumor, and treatment factors predicting resolution.</p><p><strong>Results: </strong>Sixty-eight percent (95% CI 57-77%) of women with CS had affected menses. Compared with unaffected women, those with irregular menses had higher total testosterone (TT) (91.0 vs 32.6 ng/dL, <i>P</i> = .02), while amenorrheic women had lower estradiol (21.2 vs 41.9 pg/mL, <i>P</i> = .01) and LH (1.0 vs 3.5 U/L, <i>P</i> = .009). Gonadotropins correlated inversely with urine free cortisol (LH: r = -0.42, FSH: r = -0.30; both <i>P</i> < .05). TT had no correlation. Menses returned to baseline in 84% (95% CI 66-94%) of 31 women without cyclic CS at median 6 months after achieving eucortisolism. Extensive pituitary exploration, pituitary irradiation, and mitotane reduced the likelihood of menses returning to baseline. A higher body mass index (42.4 vs 30.8 kg/m², <i>P</i> < .0001) predicted a delayed (>6 months) return to baseline.</p><p><strong>Conclusion: </strong>Two-thirds of women with CS have menstrual dysfunction due to cortisol-induced suppression of gonadotropins. In most women with minimal pituitary damage, menses return to baseline after a median of 6 months of eucortisolism. Significant overweight can delay resolution.</p>","PeriodicalId":17334,"journal":{"name":"Journal of the Endocrine Society","volume":"10 9","pages":"bvag192"},"PeriodicalIF":4.4,"publicationDate":"2026-08-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13504277/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148818730","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Adiposity, not chronological aging, is the dominant determinant of circulating testosterone in US adult men.","authors":"Adam W Potter, Karl E Friedl","doi":"10.1210/jendso/bvag194","DOIUrl":"10.1210/jendso/bvag194","url":null,"abstract":"<p><strong>Context: </strong>Age-related decline in serum testosterone is commonly cited as justification for testosterone replacement therapy, yet adiposity may represent a major modifiable determinant of circulating testosterone.</p><p><strong>Objective: </strong>To quantify the relative contributions of age, total adiposity, and visceral adiposity to circulating testosterone concentrations and prevalence of biochemical low testosterone in US adult men.</p><p><strong>Design: </strong>Cross-sectional nationally representative analysis.</p><p><strong>Setting: </strong>National Health and Nutrition Examination Survey (NHANES) 2011-2016.</p><p><strong>Participants: </strong>Men aged 20 to 59 years with valid serum testosterone measurements (<i>n</i> = 4984).</p><p><strong>Main outcome measures: </strong>Total testosterone (ng/dL) and the prevalence of biochemical low testosterone (testosterone <300 ng/dL).</p><p><strong>Results: </strong>Age explained only 2.5% of the variation in circulating testosterone (pseudo-<i>R</i> ² = 0.025). In contrast, dual-energy X-ray absorptiometry (DXA)-derived total percent body fat and visceral adipose tissue (VAT), and waist circumference each explained ∼18% to 20% of testosterone variability. Waist circumference demonstrated slightly greater explanatory performance than DXA-derived VAT, indicating that simple anthropometric assessment captures much of the clinically relevant information provided by advanced imaging. Similar inverse associations were observed using multiple biochemical testosterone thresholds (300, 250, 200, and 150 ng/dL). Biochemically low testosterone was consistently associated with substantially greater adiposity across all age groups.</p><p><strong>Conclusion: </strong>Measures of adiposity consistently demonstrated substantially stronger associations with circulating testosterone than chronological age alone. Waist circumference performed comparably to DXA-derived VAT, supporting its use as a clinically accessible marker of obesity-related testosterone suppression.</p>","PeriodicalId":17334,"journal":{"name":"Journal of the Endocrine Society","volume":"10 9","pages":"bvag194"},"PeriodicalIF":4.4,"publicationDate":"2026-08-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13519042/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148840625","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Weekly somatrogon vs daily somatropin: a propensity score-matched analysis of growth outcomes from clinical data vs KIGS.","authors":"Cheri L Deal, Mohamad Maghnie, Ronnie Wang, Martin Ove Carlsson, Michael P Wajnrajch, Lawrence A Silverman, Michel Polak, Daria La Torre, José F Cara, Bradley S Miller","doi":"10.1210/jendso/bvag186","DOIUrl":"10.1210/jendso/bvag186","url":null,"abstract":"<p><strong>Objectives: </strong>Somatrogon is a long-acting growth hormone utilized for treatment of pediatric patients with growth hormone deficiency (GHD). This matched cohort analysis compared the first 3 years of height outcomes for somatrogon-treated patients from a Phase 3 somatrogon study (NCT02968004) with historical data from somatropin-treated patients in the Kabi/Pfizer International Growth Study (KIGS).</p><p><strong>Methods: </strong>In the somatrogon study, patients with GHD were randomized to once-weekly somatrogon (0.66 mg/kg/week) or once-daily somatropin (0.24 mg/kg/week) for 12 months, followed by an open-label extension, during which all patients received somatrogon (0.66 mg/kg/week or lower dose as per protocol). Patients in the somatrogon study (somatrogon cohort) were matched with patients with GHD from KIGS (KIGS cohort) who had received somatropin (0.20-0.30 mg/kg/week), using propensity score matching according to baseline characteristics of geographic region, gender, age, peak GH, and height standard deviation score (HtSDS) (ie, peak GH and HtSDS at study entry).</p><p><strong>Results: </strong>155 patients in the somatrogon study were matched to 155 somatropin-treated patients from KIGS. The somatrogon and KIGS cohorts had similar mean annualized height velocity through Years (Y) 1 to 3 of treatment (Y1: 10.03 vs 9.57; Y2: 7.70 vs 7.33; Y3: 7.15 vs 6.56). Mean changes in HtSDS (from baseline) through Y1-3 were comparable between both cohorts, though the somatrogon cohort appeared to have larger changes in Y2-3.</p><p><strong>Conclusion: </strong>Somatrogon-treated patients in the Phase 3 study had similar height outcomes compared with matched somatropin-treated patients in KIGS, strengthening the expectation that once-weekly somatrogon will have comparable efficacy to somatropin in real-world treatment of pediatric patients with GHD.</p>","PeriodicalId":17334,"journal":{"name":"Journal of the Endocrine Society","volume":"10 9","pages":"bvag186"},"PeriodicalIF":4.4,"publicationDate":"2026-08-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13519046/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148840659","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Dual phenotype in a patient with adult-onset hyperinsulinism and diabetes caused by an activating <i>MAFA</i> variant.","authors":"Evgenia Globa, Jessica R Hopkinson, Christine S Flaxman, Michaelis Vasiliadis, Sarah J Richardson, Kurt Højlund, Sönke Detlefsen, Sarah E Flanagan","doi":"10.1210/jendso/bvag145","DOIUrl":"10.1210/jendso/bvag145","url":null,"abstract":"<p><strong>Context: </strong>The coexistence of diabetes and hyperinsulinemic hypoglycemia (HI) within a family is rare. Activating <i>MAFA</i> variants have been described in 3 families with this dual phenotype and are associated with sex-dependent clinical patterns.</p><p><strong>Methods: </strong>We studied a family where members were affected by HI (n = 5), diabetes (n = 5), or both conditions (n = 1). Clinical, biochemical, and imaging data were collected. Genetic testing for variants in known monogenic diabetes and HI genes was performed in the proband, followed by cascade testing in available relatives. Pancreatic tissue was examined by immunohistochemistry and immunofluorescence.</p><p><strong>Results: </strong>A heterozygous, p.(Ser64Phe) <i>MAFA</i> variant was identified in the male proband, who had presented with diabetes at 28 years and developed HI due to insulinomatosis 6 years later. The variant was confirmed in 5 relatives, 4 with HI and 1 with diabetes (including obligate heterozygotes). Among the 5 presenting with HI, 3 were female, whereas 4 of 6 presenting with diabetes were male, consistent with reported sex-dependent patterns.Increased nuclear expression of the transcription factor MafA (MAFA) was detected by immunofluorescence in insulin-positive tumor regions compared to the adjacent islets, supporting a pathogenic role for the variant in beta-cell regulation.</p><p><strong>Conclusion: </strong>We describe the fourth family with a pathogenic <i>MAFA</i> variant and the second individual with the dual phenotype of diabetes and HI. Our findings highlight challenges in clinical management of this condition and underscore the need to consider <i>MAFA</i> in cases of adult-onset HI or those with an atypical course of diabetes especially when there is family history.</p>","PeriodicalId":17334,"journal":{"name":"Journal of the Endocrine Society","volume":"10 9","pages":"bvag145"},"PeriodicalIF":4.4,"publicationDate":"2026-08-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13457921/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148712975","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Functional assessment of a constitutively activating <i>CASR</i> variant causing autosomal dominant hypocalcemia.","authors":"Bryan K Ward, Bronwyn G A Stuckey, John P Walsh, Arthur D Conigrave, Suzanne J Brown, Scott G Wilson","doi":"10.1210/jendso/bvag164","DOIUrl":"10.1210/jendso/bvag164","url":null,"abstract":"<p><strong>Context: </strong>A rare cause of hypocalcemia, autosomal dominant hypocalcemia type 1 (ADH1) arises from a gain-of-function variant of the calcium-sensing receptor gene (<i>CASR</i>).</p><p><strong>Objective: </strong>Three patients from 2 unrelated families, presenting with hypocalcemia and other biochemical parameters consistent with ADH1, were examined for variants in the <i>CASR</i> with the aim to functionally assess any variant detected to confirm the ADH1 diagnosis.</p><p><strong>Methods: </strong>Sanger sequencing of the coding region of the <i>CASR</i> from the 3 patients identified a single <i>CASR</i> variant that was generated by site-directed-mutagenesis in the <i>CASR</i> as a FLAG-tagged construct in the mammalian expression vector pcDNA3.1. The variant's expression in HEK293 cells (compared to FLAG-tagged wild-type [WT] receptor) was assessed by Western blot analysis and its activity measured following calcium dosing experiments using an IP-One enzyme-linked immunosorbent assay.</p><p><strong>Results: </strong>Sequence analysis revealed the presence of a heterozygous missense variant in the <i>CASR</i>, an adenine to guanine transition at nucleotide 1256 causing an asparagine to serine substitution at amino acid 419 (N419S) in the CaSR's Venus flytrap domain in all 3 patients. The N419S variant showed a modest increase in expression compared to the WT receptor. Significantly, the IP-One assay demonstrated that the variant is constitutively active in the absence of Ca⁺⁺ ions and that this gain-of-function is maintained at physiologically relevant Ca⁺⁺ ion concentrations.</p><p><strong>Conclusion: </strong>The N419S <i>CASR</i> variant affecting 2 separate families is constitutively activating and therefore causative of ADH1. This is the first report of a constitutively active variant affecting the extracellular domain of the CaSR.</p>","PeriodicalId":17334,"journal":{"name":"Journal of the Endocrine Society","volume":"10 9","pages":"bvag164"},"PeriodicalIF":4.4,"publicationDate":"2026-08-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13487326/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148794866","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pancreatic neuroendocrine tumors in patients with tuberous sclerosis: a multicenter study and systematic review.","authors":"Kalyan Mansukhbhai Shekhda, John Howat, Yujia Gao, Anat Bel-Ange, Simona Grozinsky-Glasberg, Gregory Kaltsas, Kai Man Alexander Ho, Aimee R Hayes, Dalvinder Mandair, Christos Toumpanakis, Efthimia Karra, Richard A Dixon, Deirdre Donnelly, Elizabeth A Jones, Colin H Jones, Finbar O'Callaghan, Asheesh Sharma, Kirsten Slaney, Aviva Frydman, Rajaventhan Srirajaskanthan, Nabil Kibrya, Martyn Caplin, Frances Elmslie, Ashley Grossman","doi":"10.1210/jendso/bvag178","DOIUrl":"10.1210/jendso/bvag178","url":null,"abstract":"<p><strong>Introduction: </strong>Pancreatic neuroendocrine tumors (pNETs) are a recognized feature of tuberous sclerosis complex (TSC). The current evidence suggests that pNETs occurring in TSC may exhibit a different clinical course from sporadic cases, but their natural history remains poorly characterized.</p><p><strong>Objective: </strong>This study aimed to characterize the demographics, clinical presentation, management, and long-term outcomes of TSC-associated-pNETs and to propose possible guidelines for surveillance and management.</p><p><strong>Materials and methods: </strong>We conducted a multicenter retrospective review of TSC-pNET patients from 6 UK TSC specialist clinics and from 3 NET referral centers, from 2008 to 2024. Data on demographics, tumor characteristics, management, and outcomes, were collected. A systematic review of the literature from 2009 to 2026 on TSC-pNETs was also performed.</p><p><strong>Results: </strong>We identified a total of 26 consecutive cases with the TSC-pNET-association in our cohort: 21 cases of pNETs from TSC specialist clinics (1.1% of the population), and 5 cases of TSC-pNETs from the NET referral centers (0.25% of the population). An additional 80 cases were identified from the published literature. We observed a wide spectrum of clinical phenotypes, with the majority being nonfunctioning pNETs (n = 24; 92%), whereas 2 patients were diagnosed with glucagonomas. Surgical intervention was the mainstay initial treatment, the indication being either functional pNETs, or large or symptomatic nonfunctioning pNETs.</p><p><strong>Conclusion: </strong>TSC-pNETs are rare and mostly nonfunctioning tumors with variable clinical behavior. Due to their uncertain malignant potential, we suggest that baseline pancreatic imaging should be incorporated into TSC surveillance, and we emphasize the need for heightened pNET surveillance and updated management recommendations.</p>","PeriodicalId":17334,"journal":{"name":"Journal of the Endocrine Society","volume":"10 9","pages":"bvag178"},"PeriodicalIF":4.4,"publicationDate":"2026-08-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13530301/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148874432","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The role of insurance status in molecular testing for thyroid nodules with indeterminate cytology.","authors":"Kelvin Memeh, Daniel Chopyk, Bryan An, Stephanie Paras, Harold W Davis, Vennila Padmanaban, Barbra S Miller, John E Phay, Bridget A Oppong, Jesse J Plascak, Caitlin E Hackett, Samantha M Ruff, Priya H Dedhia","doi":"10.1210/jendso/bvag179","DOIUrl":"10.1210/jendso/bvag179","url":null,"abstract":"<p><strong>Objective: </strong>The aim of the study was to evaluate the effect of health insurance status on rate of molecular testing (MT) and subsequent thyroidectomy in patients with indeterminate thyroid nodules in a real-world high-volume clinical setting.</p><p><strong>Methods: </strong>This is a single-center, retrospective study of patients who underwent fine-needle aspiration and had Bethesda III-IV cytology results between 2014 and 2022. We excluded patients with prior thyroid cancer, thyroidectomy, or incomplete insurance data. We utilized multivariable logistic regression to identify significant predictors of MT utilization and surgical intervention; specifically examining the role of insurance status and clinical symptoms.</p><p><strong>Results: </strong>A total of 448 patients were included (median age: 52 years, 79% women) with 79% of patients undergoing MT; with an associated 27-percentage-point (34% vs 61%, <i>P</i> < .001) reduction in thyroidectomy. Lack of MT was the strongest predictor of surgery (adjusted odds ratios [aOR]: 4.50, 95% confidence interval [CI]: 2.71-7.47, <i>P</i> < .001). However, uninsured/self-pay patients had 68% lower odds of MT (aOR: 0.32, 95% CI: 0.12-0.88, <i>P</i> = .026) and approximately 19-percentage-point higher thyroidectomy rate compared to insured patients (59% vs 40%). Thyroid-related compression symptoms were also significantly associated with increased rate of thyroidectomy (aOR: 1.86, <i>P</i> = .007) and an appropriate reduction in MT utilization (aOR: 0.62, <i>P</i> = .046).</p><p><strong>Conclusion: </strong>Despite high MT penetration at an academic medical center, lack of health insurance poses a critical barrier to evidence-based risk stratification leading to higher rates of diagnostic lobectomy. While symptoms appropriately drove surgical management, expanding affordable MT access may mitigate barriers to care for patients with thyroid nodules.</p>","PeriodicalId":17334,"journal":{"name":"Journal of the Endocrine Society","volume":"10 9","pages":"bvag179"},"PeriodicalIF":4.4,"publicationDate":"2026-08-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13504264/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148818782","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Longitudinal Knowledge Assessment as a driver for learning: insights from a nationwide survey of endocrinologists.","authors":"Bradley Michael Gray, Junhui Qian, Weifeng Weng, Benjamin Jacob Chesluk, Brendan Joel Barnhart, Rebecca Sue Lipner, Rozalina Grubina McCoy","doi":"10.1210/jendso/bvag176","DOIUrl":"10.1210/jendso/bvag176","url":null,"abstract":"<p><strong>Context: </strong>The American Board of Internal Medicine (ABIM) started offering the Longitudinal Knowledge Assessment (LKA) to endocrinologists as a 10-year Maintenance of Certification alternative in 2022. Participants answer 30 open-book online questions quarterly, receive real-time question-specific feedback and overall feedback via progress reports starting in year 2, and are assessed for competency every 5 years.</p><p><strong>Objective: </strong>To examine whether the LKA encouraged learning, motivated further study, and/or changed patient care.</p><p><strong>Design: </strong>We surveyed endocrinologists in 2024 who started LKA in 2022-2024 about their learning, study motivated by progress report feedback, patient care changes, and changes in the use of information resources. Results were weighted for nonresponse.</p><p><strong>Setting: </strong>Mid-career endocrinologists.</p><p><strong>Intervention: </strong>ABIM's LKA.</p><p><strong>Main outcomes: </strong>Reports of learning, motivated study, and patient care changes.</p><p><strong>Results: </strong>We surveyed 1649 endocrinologists, of whom 1015 responded to the survey (62% response). Overall, 95% of respondents reported learning while answering questions. Of those viewing their progress reports, 68% reported that they were motivated to study by the feedback. Motivated study was 17 percentage points greater for physicians with bottom vs top quartile first progress report preliminary scores. Additionally, 53% of physicians reported that LKA participation resulted in changes or planned changes to patient care. These reports were about 30 percentage points greater among physicians reporting that participation led to changes in the use of information resources, learning broader than question level, learning from question references, and study motivated by progress report feedback.</p><p><strong>Conclusion: </strong>Endocrinologists' LKA participation resulted in self-reports of patient care changes, broad learning, and motivated study.</p>","PeriodicalId":17334,"journal":{"name":"Journal of the Endocrine Society","volume":"10 9","pages":"bvag176"},"PeriodicalIF":4.4,"publicationDate":"2026-08-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13487333/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148794853","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correction to: \"Alpha-klotho, Insulin Resistance, and Adiposity Among Older Adults\".","authors":"","doi":"10.1210/jendso/bvag169","DOIUrl":"https://doi.org/10.1210/jendso/bvag169","url":null,"abstract":"<p><p>[This corrects the article DOI: 10.1210/jendso/bvag140.].</p>","PeriodicalId":17334,"journal":{"name":"Journal of the Endocrine Society","volume":"10 8","pages":"bvag169"},"PeriodicalIF":4.4,"publicationDate":"2026-07-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13420196/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148630942","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}